Lawrence Saperstein, MD
Nuclear Medicine
Titles
- Associate Professor of Radiology and Biomedical Imaging
- Chief, Nuclear Medicine
Education & Training
- FellowshipColumbia Presbyterian Medical Center (2001)
- ResidencyColumbia Presbyterian Medical Center (2000)
- InternshipStanford University Medical Center (1994)
- MDDuke University School of Medicine (1993)
Additional Information
Board Certifications
- AB of Nuclear Medicine, Nuclear Medicine (2011, recertified: 2013)
- AB of Radiology, Diagnostic Radiology (2000)
Publications
- Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.
- Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.
- Pouliot F, Gorin M, Rowe S, Saperstein L, Denes B, DiPippo V, Stambler N, Morris M, Siegel B. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. Journal Of Clinical Oncology 2023, 41: 61-61. DOI: 10.1200/jco.2023.41.6_suppl.61.
- Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score. Journal Of Clinical Oncology 2022, 40: 5024-5024. DOI: 10.1200/jco.2022.40.16_suppl.5024.
- Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score. Journal Of Clinical Oncology 2022, 40: 35-35. DOI: 10.1200/jco.2022.40.6_suppl.035.
- Liu H, Yousefi H, Mirian N, Lin M, Menard D, Gregory M, Aboian M, Boustani A, Chen M, Saperstein L, Pucar D, Kulon M, Liu C. PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients. IEEE Transactions On Radiation And Plasma Medical Sciences 2021, 6: 766-770. PMID: 37284026, PMCID: PMC10241407, DOI: 10.1109/trpms.2021.3131999.
- Carroll P, Probst S, Rowe S, Gorin M, Pienta K, Saperstein L, Pouliot F, Patnaik A, Preston M, Alva A, Stambler N, Siegel B, Morris M. MP11-11 CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL. Journal Of Urology 2021, 206: e181-e182. DOI: 10.1097/ju.0000000000001984.11.
- Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 5023-5023. DOI: 10.1200/jco.2021.39.15_suppl.5023.
- Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: e17003-e17003. DOI: 10.1200/jco.2021.39.15_suppl.e17003.
- Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: 32-32. DOI: 10.1200/jco.2021.39.6_suppl.32.
- Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 33-33. DOI: 10.1200/jco.2021.39.6_suppl.33.
- Morris M, Carroll P, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Gorin M, Siegel B. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). Journal Of Clinical Oncology 2020, 38: 5501-5501. DOI: 10.1200/jco.2020.38.15_suppl.5501.
- Gorin* M, Siegel B, Rowe S, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Carroll P. LBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000958.012.
- Pouliot F, Carroll P, Probst S, Pienta K, Rowe S, Saperstein L, Siegel B, Patnaik A, Preston M, Alva A, Gorin M, Morris M. A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. Journal Of Clinical Oncology 2020, 38: 9-9. DOI: 10.1200/jco.2020.38.6_suppl.9.
- Morris M, Durack J, Alva A, Vargas H, Piert M, Pachynski R, Pouliot F, Beauregard J, Preston M, Choudhury A, Saperstein L, Carroll P, Rowe S, Pienta K, Lin T, Wong V, Nichols M, Jensen J, Siegel B. Diagnostic performance of 18 F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC). Journal Of Clinical Oncology 2019, 37: 5012-5012. DOI: 10.1200/jco.2019.37.15_suppl.5012.
- Morris M, Pouliot F, Saperstein L, Rowe S, Gorin M, Josephson D, Wong J, Carroll P, Lin T, Stambler N, Wong V, Jensen J, Siegel B. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). Journal Of Clinical Oncology 2019, 37: tps5093-tps5093. DOI: 10.1200/jco.2019.37.15_suppl.tps5093.
- Gorin* M, Pienta K, Siegel B, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Durack J, Rowe S, Nichols M, Lin T, Strack T, DiPippo V, Mahmood S, Jensen J, Wong V, Morris M. PD60-10 A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF 18 F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER – EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY). Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557215.99831.87.
- Ellis* W, Donnelly B, Gorin M, Pouliot F, Nguyen H, Carroll P, Scherr D, Probst S, Saperstein L, Fleshner N, Maroni P, Shah K, Stambler N, DiPippo V, Strack T, Mahmood S, Jensen J, Wong V, Allaf M. PD60-11 A PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 99M TC-MIP-1404 SPECT/CT IMAGING TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH BIOPSY PROVEN LOW GRADE PROSTATE CANCER WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE (PROSPECT-AS). Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557222.99762.6b.
- Schobert I, Chapiro J, Nezami N, Hamm C, Gebauer B, Lin M, Pollak J, Saperstein L, Schlachter T, Savic L. 03:45 PM Abstract No. 117 Quantitative baseline imaging biomarkers for Yttrium-90 distribution on bremsstrahlung SPECT and tumor response prediction after radioembolization. Journal Of Vascular And Interventional Radiology 2019, 30: s55. DOI: 10.1016/j.jvir.2018.12.164.
- Morris M, Carroll P, Probst S, Pouliot F, Saperstein L, Siegel B, Alva A, Preston M, Patnaik A, Gorin M, Durack J, Nichols M, Lin T, Strack T, DiPippo V, Jensen J, Mahmood S, Wong V, Pienta K. A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY). Journal Of Clinical Oncology 2018, 36: tps5092-tps5092. DOI: 10.1200/jco.2018.36.15_suppl.tps5092.
Titles
- Associate Professor of Radiology and Biomedical Imaging
- Chief, Nuclear Medicine
Education & Training
- FellowshipColumbia Presbyterian Medical Center (2001)
- ResidencyColumbia Presbyterian Medical Center (2000)
- InternshipStanford University Medical Center (1994)
- MDDuke University School of Medicine (1993)
Additional Information
Board Certifications
- AB of Nuclear Medicine, Nuclear Medicine (2011, recertified: 2013)
- AB of Radiology, Diagnostic Radiology (2000)
Publications
- Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.
- Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.
- Pouliot F, Gorin M, Rowe S, Saperstein L, Denes B, DiPippo V, Stambler N, Morris M, Siegel B. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. Journal Of Clinical Oncology 2023, 41: 61-61. DOI: 10.1200/jco.2023.41.6_suppl.61.
- Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score. Journal Of Clinical Oncology 2022, 40: 5024-5024. DOI: 10.1200/jco.2022.40.16_suppl.5024.
- Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score. Journal Of Clinical Oncology 2022, 40: 35-35. DOI: 10.1200/jco.2022.40.6_suppl.035.
- Liu H, Yousefi H, Mirian N, Lin M, Menard D, Gregory M, Aboian M, Boustani A, Chen M, Saperstein L, Pucar D, Kulon M, Liu C. PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients. IEEE Transactions On Radiation And Plasma Medical Sciences 2021, 6: 766-770. PMID: 37284026, PMCID: PMC10241407, DOI: 10.1109/trpms.2021.3131999.
- Carroll P, Probst S, Rowe S, Gorin M, Pienta K, Saperstein L, Pouliot F, Patnaik A, Preston M, Alva A, Stambler N, Siegel B, Morris M. MP11-11 CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL. Journal Of Urology 2021, 206: e181-e182. DOI: 10.1097/ju.0000000000001984.11.
- Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 5023-5023. DOI: 10.1200/jco.2021.39.15_suppl.5023.
- Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: e17003-e17003. DOI: 10.1200/jco.2021.39.15_suppl.e17003.
- Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: 32-32. DOI: 10.1200/jco.2021.39.6_suppl.32.
- Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 33-33. DOI: 10.1200/jco.2021.39.6_suppl.33.
- Morris M, Carroll P, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Gorin M, Siegel B. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). Journal Of Clinical Oncology 2020, 38: 5501-5501. DOI: 10.1200/jco.2020.38.15_suppl.5501.
- Gorin* M, Siegel B, Rowe S, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Carroll P. LBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000958.012.
- Pouliot F, Carroll P, Probst S, Pienta K, Rowe S, Saperstein L, Siegel B, Patnaik A, Preston M, Alva A, Gorin M, Morris M. A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. Journal Of Clinical Oncology 2020, 38: 9-9. DOI: 10.1200/jco.2020.38.6_suppl.9.
- Morris M, Durack J, Alva A, Vargas H, Piert M, Pachynski R, Pouliot F, Beauregard J, Preston M, Choudhury A, Saperstein L, Carroll P, Rowe S, Pienta K, Lin T, Wong V, Nichols M, Jensen J, Siegel B. Diagnostic performance of 18 F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC). Journal Of Clinical Oncology 2019, 37: 5012-5012. DOI: 10.1200/jco.2019.37.15_suppl.5012.
- Morris M, Pouliot F, Saperstein L, Rowe S, Gorin M, Josephson D, Wong J, Carroll P, Lin T, Stambler N, Wong V, Jensen J, Siegel B. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). Journal Of Clinical Oncology 2019, 37: tps5093-tps5093. DOI: 10.1200/jco.2019.37.15_suppl.tps5093.
- Gorin* M, Pienta K, Siegel B, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Durack J, Rowe S, Nichols M, Lin T, Strack T, DiPippo V, Mahmood S, Jensen J, Wong V, Morris M. PD60-10 A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF 18 F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER – EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY). Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557215.99831.87.
- Ellis* W, Donnelly B, Gorin M, Pouliot F, Nguyen H, Carroll P, Scherr D, Probst S, Saperstein L, Fleshner N, Maroni P, Shah K, Stambler N, DiPippo V, Strack T, Mahmood S, Jensen J, Wong V, Allaf M. PD60-11 A PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 99M TC-MIP-1404 SPECT/CT IMAGING TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH BIOPSY PROVEN LOW GRADE PROSTATE CANCER WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE (PROSPECT-AS). Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557222.99762.6b.
- Schobert I, Chapiro J, Nezami N, Hamm C, Gebauer B, Lin M, Pollak J, Saperstein L, Schlachter T, Savic L. 03:45 PM Abstract No. 117 Quantitative baseline imaging biomarkers for Yttrium-90 distribution on bremsstrahlung SPECT and tumor response prediction after radioembolization. Journal Of Vascular And Interventional Radiology 2019, 30: s55. DOI: 10.1016/j.jvir.2018.12.164.
- Morris M, Carroll P, Probst S, Pouliot F, Saperstein L, Siegel B, Alva A, Preston M, Patnaik A, Gorin M, Durack J, Nichols M, Lin T, Strack T, DiPippo V, Jensen J, Mahmood S, Wong V, Pienta K. A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY). Journal Of Clinical Oncology 2018, 36: tps5092-tps5092. DOI: 10.1200/jco.2018.36.15_suppl.tps5092.